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Essentials
• Retinal vein occlusion (RVO), characterized by blood
hyperviscosity, has an unclear pathogenesis.
• We aimed to find out if hemorheological profile is
altered by oxidative stress in RVO patients.
• Red blood cell (RBC) oxidative stress is associated to
whole blood viscosity and RBC deformability.
• Reactive oxygen species alter RBC membrane rigidity,
playing a key role in RVO pathogenesis.
Summary. Background: Retinal vein occlusion (RVO) is
characterized by vision loss resulting from hypoperfusion
and hypoxia of the retina. RVO pathogenesis is not yet
fully understood, although blood hyperviscosity has been
observed. Erythrocyte deformability plays a key role in
determining blood viscosity, and it is critical to microvas-
cular perfusion and oxygen delivery. It has been shown
that oxidative stress-induced erythrocyte membrane
fluidity alterations are linked to the progression of cardio-
vascular diseases. Objectives: To determine whether
erythrocytes from RVO patients show signs of oxidative
stress, and whether this condition can modify the
hemorheologic profile in these patients. Patients and
Methods: We analyzed the entire hemorheologic profile
and erythrocyte oxidative stress – reactive oxygen species
(ROS) production and membrane lipid peroxidation – in
128 RVO patients and 128 healthy subjects, matched for
age and sex. Fluorescence anisotropy was used to evalu-
ate the fluidity of erythrocyte membranes. Results: In
RVO patients, erythrocyte oxidative stress was present
and positively correlated with whole blood viscosity and
erythrocyte deformability. Multivariate linear regression
analysis after adjustment for age, cardiovascular risk fac-
tors, medications, leukocyte number and mean corpuscu-
lar volume indicated that erythrocyte-derived ROS and
erythrocyte lipid peroxidation were significantly and posi-
tively correlated with erythrocyte membrane viscosity and
deformability. Moreover, in vitro experiments demon-
strated that ROS have a key role in erythrocyte mem-
brane fluidity. Conclusions: Our findings indicate that
erythrocyte oxidative stress plays a key role in the patho-
genesis of RVO, and pave the way to new therapeutic
interventions.
Keywords: blood viscosity; erythrocyte deformability;
erythrocyte membrane; oxidative stress; retinal vein
occlusion.
Introduction
Retinal vascular occlusive diseases develop when terminal
veins or arteries are occluded, resulting in hypoperfusion
and hypoxia of the inner retina. To date, the pathogenesis
of retinal vein occlusion (RVO) has not yet been defined.
Central RVO and branch RVO are associated with
common cardiometabolic risk factors, such as diabetes
mellitus, systemic hypertension, and atherosclerotic car-
diovascular disease [1,2]. In addition, alterations in fibri-
nolytic pathways and methionine metabolism appear to
play a significant role in the pathogenesis of this disease
[3–9], but the results are conflicting. An important issue
to consider in the pathogenesis of RVO is that of rheo-
logic alterations (high hematocrit, high plasma viscosity,
high erythrocyte aggregation, and reduced erythrocyte
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deformability). Indeed, the capillaries of the retinal
periphery are of a lower caliber than the size of erythro-
cytes, and only very elastic erythrocytes that can shift
shape can go through them. Additionally, changes in
plasma viscosity are extremely important: patients
affected by hyperviscosity syndrome can show bilateral
central RVO [10,11].
Erythrocyte aggregation is one of the principal determi-
nants of blood viscosity at low shear rates (slow flow).
The retinal venous circulation, which is characterized by
a slow circulatory rate and a high resistance to flow, cre-
ates a favorable environment for the formation of ery-
throcyte aggregates. Only a few studies have investigated
hemorheologic variables in RVO patients as compared
with healthy controls [5,12]. In a case–control study car-
ried out in RVO patients, we found a significant associa-
tion between hemorheologic alterations and the
occurrence of RVO [11]; in addition, some articles have
reported a beneficial role for hemodilution therapy
[12,13]. The role of oxidative stress in RVO patients has
been poorly explored [14,15], and its contribution to
hemorheologic abnormalities is still unknown. The objec-
tive of the present study was to determine whether ery-
throcytes from RVO patients show signs of oxidative
stress, and whether this condition is associated with an
altered hemorheologic profile.
Materials and methods
Study population
The study population comprised 128 consecutive patients
with a diagnosis of RVO who had been referred to the
Thrombosis Center of the University of Florence, Italy.
RVO was diagnosed in all patients within a period rang-
ing from 1 month to 3 months before the examination, at
the Department of Oto-Neuro-Ophthalmogical Surgical
Sciences of the University of Florence, Italy. RVO was
diagnosed by ophthalmoscopic fundus examination
revealing disk swelling, venous dilatation or tortuosity,
retinal hemorrhages, and cottonwool spots. The control
population was composed of 128 healthy subjects selected
to be comparable in age and sex with patients from the
staff of the University of Florence and/or from their
friends or partners. Patients and healthy subjects with a
personal history of glaucoma or cardiovascular disease
were excluded from the study. In order to identify symp-
tom-free subjects and patients to exclude who were sus-
pected of having any form of vascular disease, a detailed
interview addressing personal and familial history was
performed. The subjects were classified as having hyper-
tension according to the guidelines of European Society
of Hypertension/European Society of Cardiology [16], or
if they reported taking antihypertensive medications, as
verified by the interviewer. Diabetic subjects were defined
according to the American Diabetes Association [17] or
on the basis of self-reported data (if confirmed by medica-
tion or chart review). Dyslipidemia was defined according
to the criteria of the ATP III Expert Panel of the US
National Cholesterol Education Program [18]. Current
smoking status was determined at the time of physical
examination. At the time of blood sampling, all patients
were receiving antiplatelet therapy (114 receiving aspirin
75–100 mg daily; 14 receiving clopidogrel 75 mg daily).
All participants providedg signed informed consent; the
study was approved by the local Ethics Committee, and
complies with the Declaration of Helsinki.
Blood measurements
Blood samples were collected from the antecubital vein into
evacuated plastic tubes (BD Biosciences, Franklin Lakes,
NJ, USA) in the morning, after an overnight fast. Plasma
samples were obtained by centrifuging blood at 2000 9 g
for 10 min at 4 °C. A complete blood cell count was
obtained by use of the Sysmex XE-2100 hematology analy-
ser (Sysmex, Kobe, Japan), and the fibrinogen concentra-
tion was assessed according to the von Clauss method.
Whole blood viscosity (WBV) was measured at 37 °C with
the Rotational Viscosimeter LS 30 (Contraves, Zurich,
Switzerland). WBV was analyzed at shear rates of 0.512 s1
and 94.5 s1. The erythrocyte filtration test was used to
determine erythrocyte deformability with a microcom-
puter-assisted filtrometer (model MF4; Myrenne, Roetgen,
Germany), as reported by Ramakrishnan et al. [19]. The
erythrocyte deformability index or elongation index (EI)
was estimated from a curve indicating erythrocyte filtration
throughout a 10-min recording in order to determine the
rheologic properties of erythrocytes when they were passed
through polycarbonate filters with 5-lm micropores
(Nucleopore, Pleasanton, CA, USA). The initial flow rate
obtained from the microcomputer-generated curves was
used for assessment of the erythrocyte EI. For the different
hemorheologic variables, intra-assay coefficients of varia-
tion were < 1.6%, and interassay coefficients of variation
were < 4.5% (reference values in our laboratory) [11].
Assessment of erythrocyte reactive oxygen species (ROS)
generation and lipid peroxidation by flow cytometry
There are many methods for the measurement of oxidant
species in cells, but the cell-permeant fluorescent probe
20,70-dichlorodihydrofluorescein diacetate (H2DCFDA) is
the gold standard for directly measuring ROS generation
in cells. H2DCFDA is responsive to hydrogen peroxide,
peroxynitrite, and hydroxyl radical. Superoxide anions
can also contribute to H2DCFDA oxidation, albeit to a
lesser extent [20]. The BODIPY 581/591 C11 fatty acid is
a sensitive fluorescent reporter for lipid peroxidation,
undergoing a shift from red to green fluorescence emis-
sion upon oxidation of the phenylbutadiene segment of
the fluorophore. This oxidation-dependent emission shift
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enables fluorescence ratio imaging of lipid peroxidation in
live cells. In general, this probe can be incorporated into
cell membranes, and is highly responsive to alkoxyl or
peroxyl radicals [21].
After collection, 3 lL of EDTA-anticoagulated blood
samples was resuspended in 87 lL of RPMI without serum
and phenol red, and incubated with anti-human gly-
cophorin A–phycoerythrin (BD Biosciences) (10 lL) at
37 °C in the dark for 15 min, according to the manufac-
turer’s protocol. Next, the cells were centrifuged at 650 x g
for 6 min at room temperature, the supernatant was dis-
carded, and the cells were washed twice in phosphate-buf-
fered saline (PBS). To determine the level of intracellular
ROS generation and lipid peroxidation, cells were incu-
bated with H2DCFDA (2.5 lM; Invitrogen, Thermo Fisher
Scientific Inc., Waltham, MA, USA) and BODIPY 581/591
C11 (5 lM; Invitrogen, Thermo Fisher Scientific Inc.) in
RPMI without serum and phenol red for 15 min at 37 °C,
respectively. After labeling, cells were washed and resus-
pended in PBS, and analyzed immediately with a FACS-
Canto flow cytometer (Becton-Dickinson, San Jose, CA,
USA). The sample flow rate was adjusted to approximately
1000 cells s1. For a single analysis, the fluorescence prop-
erties of 100 000 erythrocytes were collected. Data were
analyzed with BD FACSDIVA software (Becton-Dickinson).
Erythrocyte membrane preparation
Erythrocyte membranes were prepared with the method
of Dodge [22], with buffer modification. Erythrocytes
were hemolyzed with 20 mM Tris–HCl buffer (pH 7.4),
supplemented with 1 mM EDTA and 0.01% phenyl-
methanesulfonyl fluoride, on ice for 15 min. The erythro-
cyte membranes were centrifuged at 20 000 9 g for
5 min. The membranes were washed several times with
the above-mentioned buffer until the ‘white ghost’ (he-
moglobin-free) state was attained. All buffers were cooled
to 4 °C prior to use, and the whole preparation procedure
was conducted on ice. The protein concentration was esti-
mated according to the method of Bradford [23]. The
concentration of protein in the sample was read from a
calibration curve in the range 50–300 lg protein mL–1,
with albumin from bovine serum as the standard.
Fluidity of erythrocyte membranes
The fluidity of erythrocyte membranes was measured by
means of fluorescence anisotropy with two fluorescent
probes: 1,6-diphenyl-1,3,5-hexatriene (DPH) and 1-[40-(tri-
methylammonium)phenyl]-6-phenyl-1,3,5-hexatriene
(TMA–DPH). DPH is localized in the hydrophobic
region near the center of the bilayer, whereas TMA–DPH
is incorporated into the polar region of the erythrocyte
membrane. Fluorescence anisotropy measurements were
carried out with an LS-55 fluorescence spectrometer
(Perkin–Elmer, Waltham, MA, USA). The excitation and
emission wavelengths were 348 nm and 426 nm, respec-
tively. The cuvette holder was temperature-controlled
(37 °C). Erythrocyte membranes were diluted with buf-
fered saline to a protein concentration of 100 lg mL1.
The final concentration of fluorescent probes was 1 lM.
The fluorescence anisotropy of probe X is defined as:
rðXÞ ¼ ðIvv Ivh GÞ=ðIvvþ 2Ivh GÞ
where Ivv and Ivh are the intensities of the fluorescence (in
arbitrary units) emitted, respectively, parallel with and per-
pendicular to the direction of the vertically polarized exci-
tation light, and G is the correction factor (G = Ihv/Ihh) for
the optical system, given by the ratio of the vertically to the
horizontally polarized emission components when the exci-
tation light is polarized in the horizontal direction. X repre-
sents, respectively, DPH or TMA–DPH. According to
Shinitzky [24], the fluorescence anisotropy values are inver-
sely proportional to cell membrane fluidity. A high degree
of fluorescence anisotropy represents a high degree of
structural order or low cell membrane fluidity.
In vitro 2,20-azobis(2-amidinopropane) dihydrochloride
(AAPH)-induced blood oxidation
To demonstrate the key role of oxidative stress in ery-
throcyte alterations, an in vitro approach was also used.
Blood samples (40 mL) from 10 control subjects were col-
lected in Vacutainer tubes containing EDTA
(0.17 mol L1). After collection, 20 mL of blood was
incubated at 37 °C for 2 h in the presence of (50 mM final
concentration) AAPH – a water-soluble azo compound
used extensively as a free radical generator – and the
remaining 20 mL of blood were maintained at 37 °C for
2 h without treatment. Following this, all experiments
were performed in treated and untreated samples.
Statistical analysis
Statistical analysis was performed with SPSS for Windows
(SPSS, Chicago, IL, USA) (Version 20.0). The non-para-
metric Mann–Whitney test for unpaired data was used for
comparisons between single groups. The v2-test was used
to test for proportions. Correlation analyses were per-
formed with Spearman’s correlation test. A logistic regres-
sion analysis was used to evaluate the risk of RVO
according to the cardiovascular risk factors, erythrocyte
ROS production, and erythrocyte membrane lipid peroxi-
dation. For logistic regression analysis, odds ratios (ORs)
and 95% confidence intervals are presented. A P-value of
< 0.05 was considered to be statistically significant. Vari-
ables showing, in the univariate logistic regression analysis,
a significant association with disease were introduced into
the multivariate logistic regression model. In order to study
the association between erythrocyte membrane viscosity
and deformability, a linear regression analysis was per-
formed by introducing age, sex, cardiovascular risk factors,
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medications, leukocyte number, MCV, erythrocyte ROS
production and erythrocyte membrane lipid peroxidation
into the linear regression model in RVO patients.
Results
The demographic and clinical characteristics of RVO
patients and healthy subjects are reported in Table S1.
Hemorheologic parameters
With regard to hemorheologic profile, a significant differ-
ence in WBV between patients and controls, analyzed at
shear rates of 0.512 s1 (24.07  3.89 versus 20.06  3.27,
P < 0.001) and 94.5 s1 (4.63  0.46 versus 4.09  0.41,
P < 0.001), was observed. The EI in patients differed sig-
nificantly from that in controls (0.343  0.026 versus
0.431  00031, P < 0.001).
Erythrocyte oxidative stress
Flow cytometry analysis was used to evaluate erythrocyte
oxidative stress. As shown in Fig. 1, erythrocytes from
RVO patients had significantly higher ROS levels than
those from healthy controls (685.5  309.7 versus
305.0  79.0, P < 0.0001). Moreover, erythrocyte mem-
brane lipid peroxidation levels in RVO patients were sig-
nificantly higher than those in controls (1431  814
versus 784  142, P < 0.0001). No significant difference
between any of the traditional risk factors were observed.
Erythrocyte membrane anisotropy
Fluorescent probes were used to evaluate the fluidity of
erythrocyte membranes. TMA–DPH and DPH, which are
known to reflect membrane fluidity in the hydrophilic
layer and in the hydrophobic core of the lipid bilayer,
102 103
FSC-A
1500 2500
2000
1500
1000
500
0
1000
500
0
Control
*
*
RVO Control RVO
Glycophorin A PE-A
100
Erythrocyte membrane
lipoperoxidation
R
BC
 m
em
br
an
e
lip
op
er
ox
id
at
io
n 
(R
FU
)
Erythrocyte ROS production
80
60
40
20
Control
RVO
Control
RVO
N
or
m
al
iz
ed
 to
 m
od
e
0
100
80
60
40
20No
rm
al
iz
ed
 to
 m
od
e
0
H2DCFDA fluorescence
Intensity
BODIPY Green fluorescence
Intensity
0
500
1000
1500
2000
Co
un
t 2500
Erythrocyte sorting analysis
Erythrocyte oxidative stress
Er
yt
hr
oc
yt
e 
R
O
S 
(R
FU
)
SS
C-
A
104 105 102 103 104 105
–103 1030 104 105
–103 1030 104 105
10
2
10
3
10
4
10
5
Fig. 1. Erythrocyte sorting strategies and representative fluorescence-activated cell sorting (FACS) plots of erythrocyte reactive oxygen species
(ROS) production and lipid peroxidation. As reported in Materials and methods, to determine the level of intracellular ROS production and
lipid peroxidation, cells were incubated with the cell-permeant fluorescent probe 20,70-dichlorodihydrofluorescein diacetate (H2DCFDA)
(2.5 lM) and BODIPY 581/591 C11 (5 lM) in RPMI without serum and phenol red for 15 min at 37 °C, respectively. After labeling, cells were
washed and resuspended in phosphate-buffered saline, and immediately analyzed with a FACSCanto flow cytometer. RFU, relative fluores-
cence units; RVO, retinal vein occlusion; PE, phycoerythrin. Group mean  standard deviation of 128 patients or 128 controls is reported.
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respectively [25,26], were applied. In Fig. 2, the analyses
of fluorescence anisotropy (r) of the erythrocyte mem-
brane are shown. DPH showed significant differences
between RVO patients (0.2778  0.0219, P < 0.0001) and
controls (0.2200  0.0227, P < 0.0001); a similar pattern
was seen with TMA–DPH, with significant differences
between RVO patients (0.2976  0.0213, P < 0.0001) and
controls (0.2580  0.0221, P<0.0001). The change in fluo-
rescent probe fluorescence anisotropy was rather small,
but was statistically significant. The effect was observed
with both fluorescent probes, which means that fluidity
changes occurred on the surfaces of membranes as well as
in the lipid core.
Correlation between investigated parameters
As shown in Fig. 3, erythrocyte-derived ROS were signifi-
cantly correlated with WBV analyzed at a shear rate of
0.512 s1 (r2 = 0.3819, P < 0.0001), with WBV analyzed at
a shear rate of 94.5 s1 (r2 = 0.2948, P < 0.0001), with the
EI (r2 = 0.2155, P < 0.0001), and with erythrocyte mem-
brane anisotropy: with DPH (r2 = 0.4581, P < 0.0001) and
with TMA–DPH (r2 = 0.4266, P < 0.0001).
Erythrocyte lipid peroxidation was significantly corre-
lated with WBV analyzed at a shear rate of 0.512 s1
(r2 = 0.2567, P < 0.0001), with WBV analyzed at a shear
rate of 94.5 s1 (r2 = 0.2000, P < 0.0001), with the EI
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Fig. 3. Correlation analysis among erythrocyte reactive oxygen species (ROS) production, whole blood viscosity (WBV) (analyzed at shear
rates of 0.512 s1 and 94.5 s1), erythrocyte deformability (elongation index [EI]) and erythrocyte membrane fluidity (with 1,6-diphenyl-1,3,5-
hexatriene [DPH] and 1-[40-(trimethylammonium)phenyl]-6-phenyl-1,3,5-hexatriene [TMA-DPH] probes) in retinal vein occlusion patients. Ery-
throcyte ROS production was positively and significantly correlated with WBV analyzed at shear rates of 0.512 s1 and 94.5 s1 (P < 0.0001)
and with erythrocyte membrane fluidity (with DPH and TMA–DPH probes) (P < 0.0001). Erythrocyte ROS production was inversely corre-
lated with erythrocyte deformability (EI) (P < 0.0001). RFU, relative fluorescence units.
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(r2 = 0.3389, P < 0.0001), and with erythrocyte membrane
anisotropy: with DPH (r2 = 0.3991, P < 0.0001) and with
TMA–DPH (r2 = 0.3943, P < 0.0001) (Fig. 4).
Figure 5 shows that DPH fluorescence anisotropy was
significantly correlated with WBV analyzed at a shear rate
of 0.512 s1 (r2 = 0.1754, P < 0.0001), with WBV analyzed
at a shear rate of 94.5 s1 (r2 = 0.1503, P < 0.0001), and
with the EI (r2 = 0.0987, P = 0.0003).
TMA–DPH fluorescence anisotropy was significantly
correlated with WBV analyzed at a shear rate of
0.512 s1 (r2 = 0.1482, P < 0.0001), with WBV analyzed
at a shear rate of 94.5 s1 (r2 = 0.1300, P < 0.0001), and
with the EI (r2 = 0.1313, P < 0.0001) (Fig. 5).
Among clinical characteristics, no correlation between
ROS production or lipid peroxidation and traditional
risk factors, platelet volume, white blood cell count,
mean corpuscular hemoglobin (MCH), MCH concentra-
tion, red distribution width, platelet count and fibrinogen
level were found.
Regression analyses
In multivariate logistic regression analysis, after adjust-
ment for several potential confounders, hypertension,
diabetes, erythrocyte-derived ROS, erythrocyte lipid per-
oxidation, DPH and TMA–DPH remained significantly
associated with RVO (Table 1).
Partial correlation coefficients between erythrocyte
oxidative stress-related parameters (ROS production and
lipid peroxidation) and erythrocyte membrane rigidity
(DPH and TMA–DPH), WBV and erythrocyte deforma-
bility (erythrocyte EI), after controlling for age, sex, car-
diovascular risk factors, medications, leukocyte number
and MCV, were determined (Table 2).
In multivariate linear regression analysis after adjust-
ment for age, sex, cardiovascular risk factors, medica-
tions, leukocyte number, and MCV, erythrocyte-derived
ROS and erythrocyte lipid peroxidation still remained sig-
nificantly and positively correlated with erythrocyte mem-
brane viscosity and deformability (Table 2).
AAPH-induced erythrocyte membrane alterations
To elucidate the mechanisms underlying the modified
hemorheologic profile in RVO patients, we performed
in vitro experiments in which we treated blood samples
from healthy subjects with the free radical generator
AAPH (Fig. 6). First, erythrocyte lipid peroxidation and
ROS production (Fig. 6A) were significantly increased as
compared with control samples (P < 0.001). Moreover, a
significant increase in fluorescent probe fluorescence ani-
sotropy in oxidized samples (P < 0.001) was found
(Fig. 6B), demonstrating the key role of oxidative stress
in altering membrane rigidity. As shown in Fig. 6C, a
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Fig. 4. Correlation analysis among erythrocyte membrane lipid peroxidation, whole blood viscosity (WBV) (analyzed at shear rates of
0.512 s1 and 94.5 s1), erythrocyte deformability (elongation index [EI]) and erythrocyte membrane fluidity (with 1,6-diphenyl-1,3,5-hexatriene
[DPH] and 1-[40-(trimethylammonium)phenyl]-6-phenyl-1,3,5-hexatriene [TMA–DPH] probes) in retinal vein occlusion patients. Erythrocyte
membrane lipid peroxidation was positively and significantly correlated with WBV analyzed at shear rates of 0.512 s1 and 94.5 s1
(P < 0.0001) and with erythrocyte membrane fluidity (with DPH and TMA–DPH probes) (P < 0.0001). Erythrocyte membrane lipid peroxida-
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significant difference in WBV analyzed at shear rates of
94.5 s1 and at 0.512 s1 was observed between treated
and untreated blood samples (P < 0.001). Similar results
(untreated versus treated blood, P < 0.001) were obtained
when the EI was measured (Fig. 6D).
Discussion
For the first time, a marked increase in erythrocyte oxida-
tive stress in RVO patients as compared with control sub-
jects has been observed. We found that, in erythrocytes
from RVO patients, ROS production and membrane lipid
peroxidation were significantly increased, and that these
parameters were positively correlated with WBV and ery-
throcyte deformability, thus contributing to the altered
hemorheologic profile in these patients. Moreover, our
in vitro experiments indicate that ROS have a key role in
erythrocyte membrane fluidity.
Oxidative stress, which occurs when the level of ROS
overwhelms antioxidant defense systems, is closely associ-
ated with several chronic and acute disorders [27,28]. The
erythrocyte, during its lifetime, is particularly exposed to
oxidative stress, owing to the high content of membrane
polyunsaturated fatty acids and to the auto-oxidation of
hemoglobin within the cell [29].
In RVO patients, signs of oxidative stress, such
as enhanced plasma lipid peroxidation (increased
thiobarbituric acid reactive substance levels) and
decreased antioxidant activity of paraoxonase, have been
reported [30]. However, the oxidative stress-related ery-
throcyte alterations in RVO patients have never been
explored. Biological membranes generally contain consid-
erable amounts of highly unsaturated lipids and choles-
terol. A prevalence of polyunsaturated fatty acids,
however, makes the membrane phospholipids potentially
susceptible to oxidation. This process disturbs the bilayer
structure, modifies membrane properties such as mem-
brane fluidity, alters the physiologic functions of cell
membranes, and contributes to cell membrane damage
[31,32]. ROS exert their damaging effects on erythrocyte
membrane polyunsaturated fatty acids, resulting in the
production of malondialdehyde, which can cause progres-
sive echinocyte transformation and increased membrane
rigidity. This accounts for reduced erythrocyte flexibility
and to microcirculatory disorders. The deformability of
erythrocytes resulting from their membrane flexibility is a
factor in maintaining normal blood flow in the microcir-
culation, allowing their transit through capillaries whose
lumen is narrower than the cell diameter [33]. A key fea-
ture of microcirculatory hemodynamics is the ability of
erythrocytes to assume a parachute-like shape in small
capillaries, and this is critically dependent on their bend-
ing and shear moduli. The deep changes induced in the
main structural components of erythrocytes hamper cell
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Fig. 5. Correlation analysis among erythrocyte membrane fluidity (with 1,6-diphenyl-1,3,5-hexatriene [DPH] and 1-[40-(trimethylammonium)
phenyl]-6-phenyl-1,3,5-hexatriene [TMA–DPH] probes), whole blood viscosity (WBV) (analyzed at shear rates of 0.512 s1 and 94.5 s1) and
erythrocyte deformability (elongation index [EI]) in retinal vein occlusion patients. Erythrocyte membrane fluidity of the hydrophobic region of
the bilayer (DPH probe) was positively and significantly correlated with WBV analyzed at shear rates of 0.512 s1 and 94.5 s1 (P < 0.0001)
and inversely correlated with erythrocyte deformability (EI) (P = 0.0003). Erythrocyte membrane fluidity of the polar region of the bilayer
(TMA–DPH probe) was positively and significantly correlated with WBV analyzed at shear rates of 0.512 s1 and 94.5 s1 (P < 0.0001) and
inversely correlated with erythrocyte deformability (EI) (P < 0.0001). RFU, relative fluorescence units.
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passage through the microcirculation, thus contributing
to microvascular complications. The major determinants
of erythrocyte deformability are cell geometry, intracellu-
lar fluid viscosity, and the viscoelastic properties of the
cell membrane [34,35]. Several articles have described a
decrease in membrane fluidity in different cell membranes
as a consequence of lipid peroxidation [36–38]. However,
the exact mechanisms by which oxidative stress affects
membrane functions remain unclear.
Two main reasons have been suggested for the loss of
membrane fluidity in oxidative stress condition. First, the
polyunsaturated/saturated fatty acid ratio in the mem-
brane could be reduced [39], because ROS have a particu-
lar affinity for electron-rich unsaturated covalent bonds,
which are found in polyunsaturated fatty acids [40]. Sec-
ond, the formation of cross-links among the membrane
lipid moieties may limit motion within the membrane,
contributing to rigidity [41]. In fact, the existence of a
direct relationship between lipid peroxidation and mem-
brane leakiness has been suggested [42–45]. Moreover,
lipid peroxidation can alter lipid membrane permeability
by increasing the dielectric constant of the membrane
interior and by increasing the microviscosity, possibly
through cross-linking of lipid radicals [46]. The effect of
peroxidation on lipid dynamics and membrane order is
still a matter of debate. According to some researchers,
peroxidation does not affect the fluidity of the membrane
[47] or the reorientational dynamics of the lipids [48].
According to others, membrane fluidity is decreased [49–
52], and the decrease is more marked near the double
bonds of the bilayer than in other regions [49]. Our
results indicate that erythrocyte membrane fluidity is sig-
nificantly altered in RVO patients as compared with con-
trols, suggesting that cell membranes are stiffer and less
fluid in RVO erythrocytes.
Erythrocyte deformability is critical to microvascular
perfusion and oxygen delivery [53]. Alterations in this
contribute to the severe vascular pathology of RVO. Fur-
thermore, because the size, shape and diffusion capacity
of an erythrocyte depend on the structure of its mem-
brane, alterations in membrane structure could lead to a
Table 1 Univariate and multivariate logistic regression analyses for retinal vein occlusion; analyses were adjusted for age and sex
Univariate analysis (controls, n = 128;
patients, n = 128)
Multivariate analysis (controls, n = 128;
patients, n = 128)
OR (95% CI) P-value OR (95% CI) P-value
Age 1.01 (0.98–1.02) 0.954 – –
Sex (F versus M)
M = 70; F = 58
0.85 (0.52–1.40) 0.531 – –
Hypertension
Patients, n = 62/128
Controls, n = 22/128
4.53 (2.54–8.05) < 0.001 9.22 (3.04–27.97) < 0.001
Dyslipidemia
Patients, n = 59/128
Controls, n = 46/128
1.52 (0.92–2.52) 0.099 – –
Diabetes
Patients, n = 16
Controls, n = 2
4.53 (2.54–8.05) < 0.001 13.74 (2.40–78.84) 0.003
Smoking habit
Patients, n = 34/128
Controls, n = 22/128
1.74 (0.95–3.19) 0.071 – –
Erythrocyte-derived ROS* 4.93 (3.22–7.55) < 0.001 6.90 (3.95–12.03) < 0.001
Erythrocyte lipid peroxidation* 1.42 (1.60) < 0.001 1.53 (1.32–1.76) < 0.001
DPH* 5.21 (3.10–8.77) < 0.001 7.69 (3.61–16.40) < 0.001
TMA–DPH* 3.11 (2.31–4.18) < 0.001 3.60 (2.51–5.16) < 0.001
CI, confidence interval; DPH, 1,6-diphenyl-1,3,5-hexatriene; F, female; M, male; OR, odds ratio; ROS, reactive oxygen species; TMA–DPH,
1-[40-(trimethylammonium)phenyl]-6-phenyl-1,3,5-hexatriene.
*OR for each 100-Unit increase.
Table 2 Partial correlation coefficients between erythrocyte oxidative
stress-related parameters (reactive oxygen species [ROS] production
and lipid peroxidation) and erythrocyte membrane rigidity (1,6-
diphenyl-1,3,5-hexatriene [DPH] and 1-[40-(trimethylammonium)phe-
nyl]-6-phenyl-1,3,5-hexatriene [TMA–DPH]), whole blood viscosity
(WBV) and erythrocyte deformability (erythrocyte elongation index
[EI]) after controlling for age, sex, cardiovascular risk factors, medi-
cations, leukocyte number, and mean corpuscular volume
Erythrocyte
ROS (RFU)
Erythrocyte
lipid peroxidation
(RFU)
DPH (RFU) r = 0.652P < 0.001 r = 0.609P < 0.001
TMA–DPH (RFU) r = 0.605P < 0.001 r = 0.593P < 0.001
WBV 0.512 s1
(mPa*s)
r = 0.593P < 0.001 r = 0.508P < 0.001
WBV 94.5 s1
(mPa*s)
r = 0.462P < 0.001 r = 0.405P < 0.001
Erythrocyte EI r =  0.455P < 0.001 r =  0.570P < 0.001
RFU, relative fluorescence units.
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decrease in tissue oxygenation [54] and retinal ischemia.
Erythrocyte deformability plays a major role in determin-
ing blood viscosity in the central retinal vein at the level
of the lamina cribrosa, where slow venous flow and high
vascular resistance are present. Interestingly, our results
show an inverse correlation between erythrocyte mem-
brane lipid peroxidation and deformability, demonstrating
that membrane peroxidation can perturb membrane prop-
erties. This evidence is also confirmed by the significant
and inverse correlation between erythrocyte ROS
production and the EI. There are several possible reasons
for the marked heterogeneity found in the literature,
including the use of different methodologies for peroxide
generation, leading to different (and usually not well
defined) membrane lipid compositions [54]. However,
despite the numerous studies on the effects of oxidation
on the structure and dynamics of lipid membranes, the
relationship between increased membrane permeability
and modifications in the structure and dynamics of lipid
bilayers is not clear.
A number of studies have demonstrated that patients
with arteriosclerosis, or high levels of plasma glucose and
high arterial blood pressure, show an increased risk of
developing RVO [55,56]. Several hemodynamic changes in
the retinal microvasculature (such as increased vascular
permeability, vasodilatation and adhesion of inflamma-
tory cells to the blood vessel wall) are associated with
hyperglycemia-induced inflammation [57,58]. Further-
more, strong evidence suggests that oxidative stress
induced by hyperglycemia is involved in the development
of vascular alterations in the retina [59]. Increased inter-
nal membrane viscosity resulting from glycosylation leads
to decreased erythrocyte deformability in patients with
diabetes [60]. In addition, it has been demonstrated that
the severity of hypertension is associated with erythrocyte
aggregation and deformability [61], and that erythrocytes
contribute to the high incidence of atherosclerotic diseases
in patients with hypertension, partly because of the asso-
ciation of erythrocyte hemorheologic alterations with
increased oxidative stress [62]. However, our statistical
analysis demonstrated that, after adjustment for several
potential confounders (including hypertension and dia-
betes), erythrocyte-derived ROS and erythrocyte lipid per-
oxidation remained significantly associated with RVO
and positively correlated with erythrocyte membrane vis-
cosity and deformability.
Some limitations of this study should be pointed out.
The control group consisted of healthy volunteers, which
may have led to higher ORs in this study. First, RVO
patients are likely to have originated from a different
source population than the healthy controls; therefore,
the variables studied may have followed a different distri-
bution than that of the population from which the
patients originated. Moreover, the size of the study
groups is limited, and these results need further confirma-
tion in a larger population. Finally, all laboratory param-
eters were evaluated on a single occasion after RVO, and,
at present, these results do not allow us to establish a def-
inite role of these alterations in the onset of RVO, owing
to the retrospective design of the study. In spite of these
limitations, our results show significant erythrocyte mem-
brane alterations in RVO patients, at the structural and
functional levels, and an increase in membrane lipid per-
oxidation and intracellular ROS production. The main
findings here reported suggest that erythrocyte oxidative
stress plays a key role in the pathogenetic mechanism of
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Fig. 6. In vitro oxidative stress-induced erythrocyte membrane alter-
ations. To demonstrate the key role of oxidative stress in erythrocyte
alterations, blood samples from 10 control subjects were incubated
(or not) at 37 °C for 2 h in the presence of the free radical generator
2,20-azobis(2-amidinopropane) dihydrochloride. Then, all experi-
ments were performed in treated and untreated samples. (A) Ery-
throcyte lipid peroxidation and erythrocyte reactive oxygen species
(ROS) production were significantly increased as compared with
unoxidized samples (P < 0.001). (B) Fluorescence anisotropy (1,6-
diphenyl-1,3,5-hexatriene [DPH] and 1-[40-(trimethylammonium)phe-
nyl]-6-phenyl-1,3,5-hexatriene [TMA–DPH]) was significantly
increased in oxidized samples (P < 0.001), demonstrating the key
role of oxidative stress in altering erythrocyte membrane rigidity. (C)
A significant difference in whole blood viscosity (WBV) at shear
rates of 94.5 s1 and at 0.512 s1 was observed between treated and
untreated blood samples (P < 0.001). (D) Erythrocyte deformability
(elongation index [EI]) was significantly reduced in oxidized samples
(P < 0.001). RFU, relative fluorescence units.
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RVO disease, and pave the way to possible therapeutic
interventions with antioxidant supplementation.
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